IFNG and lip and oral cavity carcinoma: Before hesperidin can be applied in clinical trials, which may offer a novel treatment option for patients with oral cancer, additional in vivo studies are required to confirm the inhibitory effect of hesperidin on the inducible PD-L1 expression by IFN-γ.